Under Dr. Anil Bhansali's clinical leadership, Gini has built one of the most rigorous Mounjaro outcomes programmes in North India. Unlike commercial weight loss clinics that prescribe Mounjaro based on patient demand, Gini's approach is data-driven — every patient is assessed against a metabolic phenotype framework before starting tirzepatide, and every outcome is tracked.
📍 Sector 69, Mohali · GLP-1 Desk: 0172 4120100 · Mon–Sat 10 AM–6 PM
Mounjaro (tirzepatide) is a dual GIP+GLP-1 agonist. Ozempic is a GLP-1 agonist only. The GIP pathway targets different receptors in fat tissue, muscle, and the pancreas — this is why Mounjaro produces significantly greater weight loss in head-to-head trials (SURMOUNT-2).
Same as Ozempic — reduces appetite via hypothalamic receptors, slows gastric emptying, stimulates insulin secretion in a glucose-dependent manner, and reduces glucagon. This is the foundational mechanism shared by all GLP-1 agonists.
GIP (glucose-dependent insulinotropic polypeptide) acts on adipocytes, muscle cells, and pancreatic beta cells through distinct receptors. It enhances fat mobilisation, improves insulin sensitivity in peripheral tissues, and provides additive glucose-lowering beyond what GLP-1 alone achieves.
The combined activation of both GLP-1 and GIP receptors produces a greater-than-additive effect on weight loss and glycaemic control. SURMOUNT-1 showed up to 22.5% weight loss at 72 weeks — substantially exceeding what semaglutide achieves at its maximum approved dose.
These are the metabolic profiles where tirzepatide shows the strongest outcomes in Gini's cohort. Not every patient needs Mounjaro — we prescribe based on phenotype, not demand.
Patients with significant obesity and Type 2 diabetes show the most dramatic dual response — both HbA1c and body weight fall substantially. This is Mounjaro's strongest evidence base.
The GIP component of Mounjaro specifically improves peripheral insulin sensitivity. Patients with high HOMA-IR scores benefit from a mechanism that GLP-1 alone cannot fully address.
When both glycaemic control and weight are significantly out of range, tirzepatide's dual action addresses both simultaneously — often reducing the need for additional insulin dose escalation.
Women with PCOS and metabolic syndrome (central obesity, insulin resistance, dyslipidaemia) show meaningful improvements in hormonal markers alongside weight loss with tirzepatide.
Patients who achieved less than 5% weight loss after 6+ months on a therapeutic semaglutide dose are excellent candidates for a switch to Mounjaro. The GIP pathway provides a genuinely different mechanism.
Emerging cardiovascular data from the SURPASS-CVOT trial shows tirzepatide's cardiovascular benefit profile. The GIP pathway is showing additional CV benefit signals in post-hoc analyses — an area Dr. Bhansali actively monitors.
Gini Cohort Data (Mounjaro Group)
In the above patient profile group, our data shows: average weight loss 13–18% of body weight at 6 months. HbA1c reduction of 2.1–2.8 percentage points. These are outcomes tracked in Dr. Bhansali's programme — not manufacturer trial data.
Tirzepatide was launched in India by Eli Lilly in March 2025. Current availability and pricing below.
KwikPen (auto-injector) and vials available. Vials also used for clinic administration under Dr. Bhansali's supervision.
⚠️ Cold Chain Warning: Do not source Mounjaro from unverified online sellers. Cold chain integrity is critical for tirzepatide efficacy and safety. Gini advises patients on verified, pharmacist-dispensed sourcing only.
Gini does not prescribe tirzepatide without a structured baseline assessment. This protects you and ensures the best outcomes.
We present real-world data from Gini's cohort, not just trial percentages. Side effects are manageable and mostly GI-related, concentrated in the first 4–8 weeks of therapy.
For full CGHS + GLP-1 coverage details, see GLP-1 & CGHS Coverage →
For a full comparison of GLP-1 drugs available at Gini, see GLP-1 Therapy Mohali — Full Drug Directory →
Data-driven prescribing. Metabolic phenotyping before we start. Outcomes tracked throughout. Not a weight loss clinic — a clinical programme. Mon–Sat, 10 AM–6 PM.